168
Participants
Start Date
March 25, 2022
Primary Completion Date
November 30, 2025
Study Completion Date
January 31, 2026
Tigertriever 13
patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO) will be treated with the Tigertriever 13 device.
RECRUITING
CUB Hôpital Erasme, Brussels
RECRUITING
NYU Langone Health, New York
RECRUITING
Mount Sinai, New York
RECRUITING
Stony Brook University, Stony Brook
RECRUITING
University of Buffalo, Buffalo
WITHDRAWN
Thomas Jefferson University, Philadelphia
RECRUITING
WellStar Research Institute, Marietta
RECRUITING
Semmes Murphey Foundation, Memphis
RECRUITING
St. Lukas hospital, Radprax, Solingen
RECRUITING
Mercy Health, Toledo
WITHDRAWN
University Hospital Knappschaftskrankenhaus, Bochum
RECRUITING
Corewell Health (Spectrum), Grand Rapids
RECRUITING
Munson Medical Center, Traverse City
RECRUITING
Universitätsklinikum Bonn, Bonn
RECRUITING
Advocate Aurora Research Institute,, Chicago
RECRUITING
Texas Stroke Institute, Plano
RECRUITING
Valley Baptist Medical Center, Harlingen
WITHDRAWN
Honor Health, Phoenix
WITHDRAWN
Carondelet St. Jospeh's Hospital, Tucson
RECRUITING
Lakewood Regional Medical Center, Los Angeles
RECRUITING
Los Robles, Thousand Oaks
WITHDRAWN
Providence Health, Fullerton
RECRUITING
Alfreid Krupp, Essen
RECRUITING
Universitätsklinikum Schleswig-Holstein, Kiel
RECRUITING
Orebro University Hospital, Örebro
Lead Sponsor
Rapid Medical
INDUSTRY